Please login to the form below
Grünenthal's Harald Stock joins OvaScience board
Provides European expertise as fertility company looks to expand beyond US
Infertility specialist OvaScience has appointed Harald Stock, CEO of German pharma firm Grünenthal, to its board of directors.
Stock, who has served in his position at Grünenthal since 2009, will provide US-based OvaScience with strong working knowledge of the European pharma market as the company looks to expand its global reach.
“The global fertility market is nearly 10 times larger than the US alone, and growing rapidly,” said Dr Michelle Dipp, CEO of OvaScience.
“Harald's expertise and success commercialising products in global healthcare markets will be important to OvaScience as we advance our ex-US strategy.”
Prior to joining Grünenthal, Stock was chairman and managing director of the German DePuy Group, the orthopaedics division of Johnson & Johnson.
He has also spent time with Roche, serving in a variety of senior positions, including senior VP of its global near patient testing business.
In addition, Stock is a board member of EFPIA and previously represented J&J on the board of BVMed, the body representing the medical technology industry in Germany.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen reports positive results for Otezla in psoriatic arthritis
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by EC for older adults
- The 17th World Congress on Controversies in Neurology
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
No results were found
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
